Uncovering novel advances for increasing resistance in anti-infective drug development: The global anti-infective market is currently estimated at $66.5 billion, with anti-bacterial agents accounting for more than 50% of sales. Many biotechs and pharmaceutical companies are seeing developments in later stage clinical trials, specifically in anti-bacterial and anti-fungal, both of which are growing in demand. The threat of bacterial resistant strains of infectious diseases continually increases and creates a race to develop an effective resistant drug to combat these strains. The Anti-Infectives Summit will discuss effective lead generation approaches currently being used in anti-bacterial, anti-viral and anti-fungal drug discovery and address which biologics may play a role in anti-infective therapy.
A search for Anti-biotics & Anti-microbialsPPRC AYUR
'N' number of anti-biotics and anti-microbials are available in the market but natural and plant origin anti-biotics and anti-microbials are the best options for cure.
penicillins - power point - History,mechanism of action,classification,chemis...Dr. Ravi Sankar
Antibiotics - Penicillin's - power point - History, mechanism of action, classification, chemistry, SAR, Nomenclature, uses, side effects- Medicinal chemistry.
Prof. P. Ravisankar M. Pharm., Ph.D.
HOD .,
Vignan Pharmacy college
vadlamudi- Guntur-A.P, India.
banuman35@gmail.com
Phone: 0 9059994000
0 9000199106
A search for Anti-biotics & Anti-microbialsPPRC AYUR
'N' number of anti-biotics and anti-microbials are available in the market but natural and plant origin anti-biotics and anti-microbials are the best options for cure.
penicillins - power point - History,mechanism of action,classification,chemis...Dr. Ravi Sankar
Antibiotics - Penicillin's - power point - History, mechanism of action, classification, chemistry, SAR, Nomenclature, uses, side effects- Medicinal chemistry.
Prof. P. Ravisankar M. Pharm., Ph.D.
HOD .,
Vignan Pharmacy college
vadlamudi- Guntur-A.P, India.
banuman35@gmail.com
Phone: 0 9059994000
0 9000199106
Antibiotics,antibiotics resistances,classification of antibiotics,misuse of antibiotics details discussed here. for more information visit my blog helpful for pharmacy and medical student.thanks.
http://mydreamlan.wordpress.com/category/education/
IQPC’s 8th Polymorphism & Crystallization Scientific Forum is aimed at helping companies to lower costs, increase efficiency and cover a broad range of successful technical case studies on crystal nucleation and polymorphism – a major issue and area of drug development for the pharmaceutical and biotech industry.
This year’s timely conference will cover over 16 in-depth sessions and case study
examples including:
• Novel Techniques for Formulating a Respiratory Drug Development Pipeline
• Differences in the Development of Small vs. Large Molecules
• Evolving Clinical Endpoints in the Development of Inhaled Corticosteroids
• Clinical Outcomes of PD4 Inhibitors: Valuable Lessons Learned
• Improving the Management of Patient Care in Asthma
• Developing Product Design for Addressing Patient Adherence and Compliance
And much more including 4+ hours of scheduled networking, insightful interactive
panel discussions and a series of interactive workshops.
Learn Best Practice Strategies On How To:
• Assess the need for innovative drug development pipelines in the respiratory market
• Uncover modern techniques for formulating a respiratory drug development pipeline
• Discover if we need new bronchodilators and anti-inflammatory drugs for the treatment of Asthma and COPD
• Develop and enhance product design for addressing patient adherence and compliance
• Discover effective strategies for improving the management of patient care in Asthma
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
Immunotherapy Europe Speakers - The Perfect Combination of Strategy and Innov...Michael Adeniya
Phacilitate's Immunotherapy Europe will bring leaders in the field together. big phama, biotech, payers, HTAs, regulators and investors. See what's being discussed at Europe's ONLY commercial meeting for Immunotherapy!
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
SciTech Development LLC - Intelligent Technology to Solve Unmet Clinical Needs - Often the difference between success and failure is the dedication and persistence of the executive team. SciTech Development’s principal asset, fenretinide, is guided by a deeply experienced team in the broad portfolio of pharmaceutical development, clinical strategy, and scientific formulation.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
Antibiotics,antibiotics resistances,classification of antibiotics,misuse of antibiotics details discussed here. for more information visit my blog helpful for pharmacy and medical student.thanks.
http://mydreamlan.wordpress.com/category/education/
IQPC’s 8th Polymorphism & Crystallization Scientific Forum is aimed at helping companies to lower costs, increase efficiency and cover a broad range of successful technical case studies on crystal nucleation and polymorphism – a major issue and area of drug development for the pharmaceutical and biotech industry.
This year’s timely conference will cover over 16 in-depth sessions and case study
examples including:
• Novel Techniques for Formulating a Respiratory Drug Development Pipeline
• Differences in the Development of Small vs. Large Molecules
• Evolving Clinical Endpoints in the Development of Inhaled Corticosteroids
• Clinical Outcomes of PD4 Inhibitors: Valuable Lessons Learned
• Improving the Management of Patient Care in Asthma
• Developing Product Design for Addressing Patient Adherence and Compliance
And much more including 4+ hours of scheduled networking, insightful interactive
panel discussions and a series of interactive workshops.
Learn Best Practice Strategies On How To:
• Assess the need for innovative drug development pipelines in the respiratory market
• Uncover modern techniques for formulating a respiratory drug development pipeline
• Discover if we need new bronchodilators and anti-inflammatory drugs for the treatment of Asthma and COPD
• Develop and enhance product design for addressing patient adherence and compliance
• Discover effective strategies for improving the management of patient care in Asthma
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
Immunotherapy Europe Speakers - The Perfect Combination of Strategy and Innov...Michael Adeniya
Phacilitate's Immunotherapy Europe will bring leaders in the field together. big phama, biotech, payers, HTAs, regulators and investors. See what's being discussed at Europe's ONLY commercial meeting for Immunotherapy!
Dear all,
I have tried putting down my view-points on benefits of Project Management system in Pharmaceutical Industry...
Please let me know what do you think.
Regards,
Megha Thakkar
SciTech Development LLC - Intelligent Technology to Solve Unmet Clinical Needs - Often the difference between success and failure is the dedication and persistence of the executive team. SciTech Development’s principal asset, fenretinide, is guided by a deeply experienced team in the broad portfolio of pharmaceutical development, clinical strategy, and scientific formulation.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
This presentation is about the current trends in pharmacy profession. It will give the brief insight about the direction in which current pharmacy market is going.
Pharma IQ’s Cold Chain & Temperature Management Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain. All new discussions will include: review of Health Canada’s revised <0069>, Canadian importation strategies, specialty logistics, stability data and risk mitigation.
The 8th Insurance Linked Securities Summit in Bermuda is a must attend meeting for the entire insurance-capital markets value chain including institutional investors, insurance and reinsurance companies, hedge funds, banks, law firms, underwriters and life settlement providers.
The structure of the conference – with dedicated tracks for the life and non-life sides of the market – ensures you walk away with two full days’ worth of strategies and solutions on the critical issues facing your market.
Attend Strategic Social Media for Healthcare to learn from industry visionaries on how to make the leap by taking your online presence to the next level, how to integrate new media efforts with traditional approaches and how to effectively engage with and attract current and future patient-consumers.
The 11th Annual Call Center Week is the fastest growing call center event in the world! This event designed to help companies create a customer-centric culture that inspires excellence and grows the top line. Attend Call Center Week and find out how to efficiently create a customer experience that produces engaged employees, drive performance improvement, leverage tools and social media for enhancing agent and customer satisfaction and prepare your organization for Voice of the Customer initiatives. Our practitioner speakers will share practical, measurable success stories needed to enhance business results.
IQPC’s 7th Timberland Investment Summit is the key meeting of the year for investment opportunities in the timberland asset class. Now in its 7th successful year, the conference brings together a comprehensive line-up of decision-makers from the entire timberland investments value chain including pension funds, hedge funds, endowments, family offices, TIMOs, REITs, forestry management companies, law firms, and banks.
Here’s a sneak peak at highlights of the 2010 program:
Highest ever participation from institutional investors, with speakers confirmed from Mass-PRIM, CPP Investment Board, TIAA CREF, APG, and Dallas Police & Fire Retirement System
Dedicated workshops on risk mitigation, carbon credits, and strategies for smaller investors
In-depth keynotes on the prospects for the US housing market, the macroeconomic outlook for timberland and the future of timberland values
Interactive roundtable discussions on the top 5 timberland investment opportunities
2010 promises to be an exciting year for the market. With an expanded program that includes 2 track dedicated to both insurance and longevity-linked investments, the 2nd ILS Summit Europe explores and debates the critical, providing investors with the information they need to invest effectively, profitably, and with confidence.
IQPC's 4th Annual Improving Solubility conference provides new solutions to measure, predict and improve solubility, ultimately maximizing time-to-market. Topics include applying lipid based formulations, overcoming physical instability, new drug delivery technologies, identifying in-vitro absorption and discovering formulations for toxicology studies.
3rd Life Settlements and Longevity SummitAbby Lombardi
IQPC’s 3rd Life Settlements & Longevity Summit has been specifically designed to help investors make sense of the opportunities and pitfalls of this investment class. Whether you’re an experienced investor or new to the market and still evaluating the suitability of the asset class, this conference delivers invaluable insights ensuring you make the best possible decisions for superior returns.
Topics will include: Federal Oversight New Investment Structures (Fusion and Sharia-Compliant products) Transitioning to the Tertiary market and many others!
8th Cold Chain Management & Temperature Control SummitAbby Lombardi
Pharma IQ’s 8th Cold Chain Management & Temperature Control Summit provides the largest and most comprehensive forum for Canadian pharmaceutical, biotech and medical device professionals involved in the temperature-controlled supply chain. Attendees are able to network with and learn from other organizations who face similar challenges in monitoring, controlling, and maintaining temperatures of products throughout the supply chain – from manufacturing, warehousing, wholesalers, pharmacies, hospitals, and ultimately to the end user.
Whether you have yet to invest in ILS, or are looking to diversify your portfolio and explore new products, the 7th Insurance Linked Securities Summit will ensure you make the right investment decisions by presenting a well-balanced perspective on the inherent risks and opportunities in the space, and the dynamic developments in technologies and tools so you can capitalize on this revolutionary asset class.
For more information, visit us at http://www.ilsnewyork.com
The Smart Metering Networking & Operations Summit provides the opportunity to exchange strategies and best practices for implementing a more stable grid – from required components to the recognition of realistic deadlines for deploying advanced technologies.
Engage with your peers to build a NEW BUSINESS MODEL for smart grid projects, ensure you are making the RIGHT INVESTMENT in technology and secure PUBLIC SUPPORT for your AMI pilots
In today’s drug development climate, clinical supply professionals face a unique set of challenges. These include adhering & complying with stringent regulations, using specialized temperature packaging and monitoring devices, evaluating cost-effective & validated distribution processes, shipping to and from research labs or hospitals and many more. The Clinical Logistics Supply conference will provide a unique opportunity to optimize logistics, overcome inefficiencies, develop safe vendor relationships and comply with US and international standards for your clinical supply chain.
IQPC’s 5th Forum on Laboratory Informatics will provide strategies for overcoming challenges, including:
- In-depth regulatory compliance guidance
- Extensive ELN deployment and roll out projects, focusing on ROI maximization and impact on business performance
- Informatics systems in the biobanking environment
- Proactive approaches to address challenges of integration and interfacing
- Integrating and embracing knowledge management and social media tools
7th Cold Chain Distribution for PharmaceuticalsAbby Lombardi
Only at the 7th Cold Chain Distribution for Pharmaceuticals, will you have the opportunity to network with the largest group of cold chain professionals, regulators and logistics providers. Key discussions include evaluating transportation strategy from top to bottom, developing KPIs & SOPs when qualifying 3PL providers, considering international shipment and import/export procedures and updates from regulatory agencies on new & proposed guidelines. Plus – don’t miss hearing from industry colleagues on Managing International Cold Clinical Supplies, during the NEW Post-Conference Focus Day.
2nd Life Settlements & Longevity SummitAbby Lombardi
IQPC’s 2nd Life Settlements & Longevity Summit has been specifically designed to help you – the investor – make sense of the opportunities and pitfalls of this exciting investment class. With more seniors turning to life settlement options and the need to diversify with an uncorrelated asset, 2009 has been a year of opportunity in these investments. However, following the life expectancy revision in 2008, many investors lost money on their portfolios and there remains widespread uncertainty regarding LEs currently in place. Whether you’re an experienced investor or new to the market and still evaluating the suitability of the asset class, this conference delivers invaluable insights from investors, fund managers, and industry experts, ensuring you make the best possible decisions for superior returns.
8th Lean Six Sigma for Pharmaceutical, Biotech & Medical Device ExcellenceAbby Lombardi
At the 8th Lean Six Sigma for Pharma, we will bring you real-world case studies that tackle the problems you are encountering, provide you with real-world solutions, and introduce you to industry peers who have been able to overcome many of the challenges Lean Six Sigma presents.
Walk away with tools for practical applications of Lean Six Sigma in R&D, transactional, business and training processes as well as along the supply chain.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. Register by December 4th
and Save up to $698
Hear from Leading
Experts Including:
David J. Payne, PhD
Vice President, Antibacterial DPU,
Infectious Diseases Center of Excellence
Anti-Infectives
in Drug Discovery
TM GlaxoSmithKline
John Finn, PhD
Chief Scientific Officer
Trius Therapeutics
Jeffrey M. Besterman, PhD
Executive Vice President,
R & D and CSO
Summit
MethylGene Inc.
Malcolm Page, PhD
January 25-27, 2010 • Philadelphia, PA Head, Biology
Basilea Pharmaceutical
International Ltd
Adam Friedman, MD
Groundbreaking Advances and Key Chief Resident, Department of Medicine,
Division of Dermatology
Opinions within Anti-Infective Drug Albert Einstein College of Medicine
Nkechi Azie, PhD
Discovery and Development Senior Medical Director
Astellas Pharma US
Baoming Jiang, DVM, PhD
Gastroenteritis & Respiratory
Viruses Lab Branch
Centers for Disease Control and
Prevention
Ly Tam Phan, PhD
Senior Director, Medicinal Chemistry
Enanta Pharmaceuticals
Nachum Kaplan, PhD
Vice President, Microbiology
Affinium Pharmaceuticals
Neil Ryder, PhD
Executive Director, Infectious Diseases
Novartis Institutes for Biomedical
Research
Paul Miller, PhD
Executive Director, Anti-Bacterials
Highlights of this program include: Pfizer
Vincent Hernandez
• Formulating an appropriate novel anti-infective drug development Senior Scientist
pipeline Medicinal Chemistry
Anacor Pharmaceuticals
• Examining the changing fortunes of antibacterial drug development William Weiss, PhD
and commercialization Director of Pre-Clinical Services
University Of North Texas Health
• Discovering where the next novel antibacterial leads will come from Science Center
Scott Mills, PhD
• Ascertaining which biologics may play a role in anti-infective therapy Principal Scientist
AstraZeneca
• Uncovering real challenges and potential solutions for multi-drug
resistant gram-negative bacteria Chris Thomson, PhD
Director, Licensing & Business
Development
Astellas Pharma Europe Ltd
Neil D. Pearson, PhD
Media Director, Medicinal Chemistry,
Partners: Antibacterial DPU, Infectious Diseases
Center of Excellence in Drug Discovery
GlaxoSmithKline
John Powers, MD
Assistant Professor of Medicine
George Washington University
School of Medicine and former Lead
Medical Officer, Antimicrobial
www.anti-infectivesummit.com Development, US FDA
2. Who will you meet at
the Summit:
Anti-Infectives
TM
Chief Scientific Officers, Vice Presidents,
Directors, Heads, Scientists, Chemists,
Research Leaders/Fellows/Advisors and
Academics specializing in:
• Microbiology
• Immunology
Infectious Diseases
Summit
•
• Medicinal Chemistry
• Clinical Pharmacology
January 25-27, 2010 • Philadelphia, PA • Drug Discovery
• New Product Development
• Scientific Affairs
• Licensing
• Antibiotics
• Infection Discovery
• Drug evaluation
• Molecular Biotechnology
Dear Colleague, • Drug Development
• Project Management
• Preclinical Development
IQPC’s Anti-Infectives Summit aim • Portfolio Management
s to provide an opportunity for R&D
from pharmaceutical, biotech and leaders • Anti-bacterial/viral/fungal and
academia to expand their knowle Microbiological Infections
anti-infectives industry as well as dge in the
ascertain new opportunities for drug
discovery.
The need for new agents to com
challenges and significant market
bat increasing drug-resistance has
created both A Special Thanks to our
opportunities for pharmaceutical Advisory Board:
manufacturers and biotechnology
companies. A more integrated app
needed from industry, academia roach is • Malcolm Page, PhD, Head, Biology,
and government to improve the
pipeline as the demand for new anti-infectives Basilea Pharmaceutical International Ltd
therapies increases. • Neil Ryder, PhD, Executive Director,
You will hear over 16 in-depth sess Infectious Diseases, Novartis Institutes for
ions and case study examples inclu Biomedical Research
•
Targeting superbugs: New Bicycloli ding:
des effective against MRSA and VRE • David J. Payne, PhD, Vice President,
•
A novel regimen for the treatment Antibacterial DPU, Infectious Diseases
of TB Center of Excellence in Drug Discovery,
•
Sustained release of nitric oxide from
hybrid nanoparticle platforms GlaxoSmithKline
•
Emerging market countries and infe Paul Miller, PhD, Executive Director,
ctious disease needs •
•
Multi-Drug Resistant Gram-Nega Anti-Bacterials, Pfizer
tive Bacteria - Real challenges and
potential solutions • Frederick P. Duncanson, MD, Senior
Director, Section Head Infectious Diseases,
•
Bacterial Fatty Acid Synthesis as targ Neurosciences Product, Creation Unit, Eisai
et for AFN-1252, a novel and
selective-spectrum Global Clinical Development
•
ntibiotics for the treatment of stap • Anne Gershon, M.D, Vice President and
hylococcal Infection President-Elect, Infectious Diseases
•
Anti-Infective drug discovery thro Society of America (IDSA)
ugh outsourcing and collaboration
s • Ronald GM Van Amsterdam, PhD,
Additionally, benefit from industry Principal Medical Scientist, Astellas Europe
presentations by AstraZeneca, Pfiz
GlaxoSmithKline, Trius Therap er, • Arturo Casadevall, MD, PhD, Professor of
eutics, Anacor Pharmaceuticals, Microbiology and Immunology and
Affinium Pharmaceuticals, Me Novartis,
thylGene, Astellas, EnantaPha Medicine, Chair, Department of
and many more pharmaceutical, rmaceuticals,
biotech and academic experts. This Microbiology and Immunology, Albert
promises to be a networking and conference Einstein College of Medicine
discussion-filled event leaving you
ideas and solutions and to help you with new • Hans-Henrik Kristensen,
discover the current novel anti-infe
drug development pipelines. ctive Senior Manager, Novozymes A/S
We look forward to seeing you in
Philadelphia in January!
Sponsorship and
Exhibition Opportunities
ractive
P Highly inte
.S Sponsorships and exhibits are excellent
e pre- opportunities for your company to showcase
and informativ its products and services to high-level, targeted
rkshops! decision-makers attending Anti-Infectives
Simon Curtis conference wo Summit. IQPC and Pharma IQ help companies
or details
Se e page 5 f
Conference Director, Pharma IQ like yours achieve important sales, marketing
and branding objectives by setting aside a
Simon.curtis@iqpc.com limited number of event sponsorships and
exhibit spaces – all of which are tailored to
assist your organization in creating a platform
to maximize its exposure at the event.
For more information on sponsoring or
exhibiting at Anti-Infectives Summit, please
contact Mario Matulich at 212-885-2719 or
2 Register online at www.anti-infectivesummit.com or call 1-800-882-8684 sponsorship@iqpc.com.
3. Main Conference Day 1 Tuesday, January 26, 2010
7:45 Registration and Coffee Novel Therapeutic Approaches and Areas
8:35 Welcome Address and 1:30 Discovering Novel Candidates Affective Against
Chairperson’s Opening Remarks Superbugs (Torezolid [TR-701] Case Study)
• Discussing effective results for the treatment of severe complicated
The Current Anti-Infective Drug Discovery & skin and skin structure infections caused by gram-positive bacteria
Development Market Landscape • Displaying positive results especially against drug-resistant strains
such as methicillin-resistant Staphylococcus aureus (MRSA)
8:45 Opening Keynote: Industry Overview - The • Describing a randomized Phase 2, double-blind, dose-ranging study
Current Shape of Anti-Bacterial R&D conducted at eight centers in the United States
• Knowing which direction the anti-bacterials market is heading • Examining overall cure rates for severe abscesses, cellulitis, and
• Examining the emergence & challenges of novel drug classes wound infections which were 96%, 97%, and 90%, respectively
• Evaluating narrow vs broad spectrum • Evaluating a second-generation oral and IV antibacterial drug in the
• Bridging the funding gap
oxazolidinone class with activity against drug-resistant, gram-
• Discussing new strategies and creative partnerships for improving
positive bacterial pathogens, including those resistant to linezolid
success John Finn, PhD, Chief Scientific Officer, Trius Therapeutics
David J. Payne, PhD, Vice President Antibacterial DPU,
Infectious Diseases Center of Excellence in Drug Discovery, 2:15 Targeting Superbugs: New Bicyclolides Effective
GlaxoSmithKline against MRSA and VRE
• Discussing recent advances in macrolide research against MRSA and
9:30 Paradise Lost, Paradise Found? - The Changing VRE
• Identifying targeted product profiles
Fortunes of Antibacterial Drug Development and • Uncovering the history and discovery of new anti-MRSA macrolides
Commercialization • Overcoming bacterial resistance
• Changing Environment & Dynamics of Antibacterial Development • In vitro and In vivo activities
and Commercialization Ly Tam Phan, PhD, Senior Director Medicinal Chemistry, Enanta
• Displaying the steps to become sustainable reinforcement as a Global
Pharmaceuticals, Inc.
Category Leader (GCL) within the infectious diseases drug discovery
arena 3:00 Towards a Novel Regimen for the Treatment of TB:
• Current trends – evolving resistance and decreasing investment levels
• Understanding current antibacterial market dynamics
An Update on PNU-100480
• Examining future pipelines and their implications
• Examining the current state of TB therapy and the challenge of
increasing medical need
Chris Thomson, PhD, Director, Licensing & Business • Displaying updates on ongoing clinical studies with PNU-100480
Development, Astellas Pharma Europe Ltd • Discussing the current status of the global TB drug candidate
portfolio
10:15 Networking Break • Evaluating novel strategies for identifying promising new TB
regimens
Novel Anti-Infective Drug Development Paul Miller, PhD, Executive Director, Anti-Bacterials, Pfizer
Approaches
3:45 Networking Break
11:00 Formulating an Appropriate Novel Anti-Infective
Drug Development Pipeline 4:30 Sustained Release of Nitric Oxide from Hybrid
• Formulating a senior management buy-in for your organization to Nanoparticle Platform: A Novel Therapeutic
fight against withdrawing from multidrug-resistant bacteria Strategy for Cutaneous Infections
development pipelines • The role of nitric oxide in host immunity/defense
• Strategically working with a partnering organization or spin-off who • Nanotechnology as a delivery system for topical therapeutics
focus specifically within certain anti-infective areas • Novel hybrid nitric oxide releasing nanoparticles
• Effectively forging a strategic biotech alliance, for optimizing the • Efficacy of nitric oxide releasing nanoparticles against Methicillin
development pipeline Resistant Staphylococcus aureus wound and soft tissue infections
• Future directions and organisms to be targeted
• Successful drug development can shoulder most of the responsibility
for developing the next generation of anti-infectives Adam Friedman, MD, Chief Resident, Department of Medicine,
• Seeking to build product portfolios within specific anti-infective Division of Dermatology, Albert Einstein College of Medicine
therapeutic areas (case study)
Nkechi Azie, MD, Senior Medical Director, Astellas Pharma US The Global Growth of Infectious Diseases
11:45 Improving Antibacterial Discovery: A Critical Path 5:15 Emerging Market Countries and Infectious Disease
for Minimizing Attrition Due to CV Liabilities Needs
• Acute functional cardiovascular toxicity: a special consideration for
• Effectively addressing the global threat of new and reemerging
infectious diseases
antibiotic drug discovery • Inducing international cooperation in identifying, controlling, and
• Understanding QT liability and Torsade de Pointes (TdP) during lead
preventing these diseases
optimization • Examining some basic problems that global campaigns against
• Role of hERG inhibition in QT prolongation and Torsade de Points
• Beyong hERG assays for predicting TdP risk: Rabbit Ventricular
emerging infectious diseases face in applying international law to
facilitate international cooperation
Wedge assay • Discussing international solutions to emerging infections
• Lead optimization for antibacterial programs with respect to acute
• Identifying common elements of global emerging-disease control
functional cardiovascular toxicity plans
Neil D. Pearson, PhD, Director Medicinal Chemistry, • Evaluating alternative international legal strategies to revising the
Antibacterial DPU, Infectious Diseases Center of Excellence in International Health Regulations
Drug Discovery, GlaxoSmithKline Baoming Jiang, DVM, PhD, Gastroenteritis & Respiratory Viruses
Lab Branch, Centers for Disease Control and Prevention
12:30 Networking Lunch
6:00 Chairperson’s Remarks and End of Day 1
3 Register online at www.anti-infectivesummit.com or call 1-800-882-8684
4. Main Conference Day 2 Wednesday, January 27, 2010
7:45 Registration and Coffee Novel Therapeutic Approaches
8:35 Welcome Address and Chairperson’s Opening 1:30 Bacterial Fatty Acid Synthesis as Target for AFN-
Remarks 1252, a Novel and Selective-Spectrum Antibiotic
for the Treatment of Staphylococcal Infection
Update on Antifungals • Unique mechanism of action, selective inhibitor of staphylococcal
fatty acid biosynthesis
8:45 Approaches to Novel Antifungal Therapies • Highly potent, optimized to inhibit the staphylococcal FabI enzyme
• Finding antifungal targets • Preclinical safety and a selective-spectrum of activity predict minimal
• Understanding the role of resistance mechanisms antibiotic treatment related adverse effects
• Biologics and other novel approaches • Orally effective in multiple mouse infection models (pneumonia,
• Evaluating approaches to modify existing antifungals (polyenes sepsis, thigh and skin abscesses)
• Well tolerated in phase 1 clinical studies
and azoles)
• Introducing novel therapies (peptides, oligonucleotides, and Nachum Kaplan, PhD, Vice President, Microbiology, Affinium
monoclonal antibodies (MAbs)) Pharmaceuticals
Neil Ryder, PhD, Executive Director, Infectious Diseases,
Novartis Institutes for Biomedical Research 2:15 Target-Based Screening: Discovery of Novel
Inhibitors of Bacterial NAD+-Dependent DNA Ligase
9:30 Addressing Serious Fungal Infections & Broad •
Discussing in vitro validation of DNA ligase as a target for high
Spectrum Clinical Candidates throughput screening
• Optimizing potency of enzyme inhibition to achieve antibacterial
• Discussing fungi present in the gastrointestinal tract (Candida) or
activity
in the environment (Aspergillus) • Linking antibacterial activity to inhibition of DNA ligase
• Displaying a novel small molecule fungal Hos2 inhibitor that
• Achieving in vivo validation of DNA ligase via efficacy in infection
enhances the activity and spectrum of current azole treatments model
against fungal pathogens when co-administered with azoles Scott Mills, PhD, Principal Scientist, AstraZeneca
• Demonstrating how MGCD290 enhances the azole susceptibility
of common fungal pathogens such as Candida and Aspergillus 3:00 Networking Break
species
• Possessing a broad-spectrum inhibitory profile for both class A and
Future Anti-Infective Drug Discovery Techniques
class C beta-lactamase enzymes, including extended spectrum & Strategies
betalactamases (ESBLs)
• Overcoming resistance in beta-lactam-resistant organisms such as
3:30 Anti-Infective Drug Discovery through
Pseudomonas aeruginosa
Jeffrey M. Besterman, PhD, Executive Vice President, R & D
Outsourcing and Collaborations
• Examining the current paradigm of anti-infective drug discovery
and CSO, MethylGene Inc. • Discussing how and why companies are moving compounds ahead
when many larger groups have downsized their infectious disease
10:15 Networking Break efforts
• Utilizing partners to help overcome significant challenges to public
Gram-Positive & Gram-Negative Bacteria healthcare arising from drug resistant bacteria
• Progression of anti-infective drug discovery and development
11:00 Multi-Drug Resistant Gram-Negative Bacteria - through the provision of a comprehensive range of highly
Real challenges and potential solutions specialized services to the pharmaceutical, biotechnology and
• Problem pathogens (drug-resistance in E. coli, K. pneumoniae, P. consumer healthcare sectors
• The use and role of the academic collaborator, scientific incubator,
aeruginosa and A. baumannii)
• Resistance mechanisms in E. coli and K. pneumoniae CRO and CMO – what they need to know to accelerate drug
• Resistance mechanisms in P. aeruginosa and A. baumannii development
• Current research collaborations for new drug discovery: Big Pharma
•
Activity of new agents, and compounds in late-stage clincal
development, against MDR and Biotech
• Activity of experimental compounds in early stage clinical
William Weiss, PhD, Director of Pre-Clinical Services, University
of North Texas Health Science Center
development
Malcolm Page, PhD, Head, Biology, Basilea Pharmaceutical
International Ltd
4:15 Addressing the Challenge of Fungal Infections:
What are our Options?
• Discussing fungi such as Aspergillus fumigatus cause a variety of
11:45 Structure-Guided Discovery of serious nosocomial infections in immunocompromised patients
(S)-3-(aminomethyl)benzo[c][1,2]oxaborol-1(3H)- •
Resulting with their resistance to antibiotics has profound clinical
ol hydrochloride (ABX): A First in Class Gram- implications
negative Antibacterial • Displaying the three antibiotic classes which are currently in clinical
• Examining structure-based design of boron-containing use for fungal infections: amphotericin, echinocandins and azoles
antibacterial agents • Examining why all of these classes have efficacy and toxicity
• Editing active site of Leucyl tRNA synthetase as a novel drug target
drawbacks
• In vitro activity of ABX against multi-drug resistant Gram negative • Identifying and discussing approaches towards achieving this include:
– Derivatization of echinocandins and azoles
bacteria
• Discussing oral efficacy of ABX in mouse thigh infection models – Potentiation by modulating resistance mechanisms targeting
Vincent Hernandez, Senior Scientist, Medicinal Chemistry, other fungal functions
– Importing insights from antiprotozoal and anticancer agents.
Anacor Pharmaceuticals
Nafsika Georgopapadakou, PhD, Vice President, Research,
NovaBay Pharmaceuticals
12:30 Networking Lunch
5:00 End of Summit & Chairperson’s Closing Remarks
4 Register online at www.anti-infectivesummit.com or call 1-800-882-8684
6. International Quality & Productivity Center
REGISTRATION CARD 535 5th Avenue, 8th Floor
New York, NY 10017
Anti-Infectives
YES! Please TM
register me for:
❑ Conference Only
Summit
❑ All Access*
❑ Conference + 1 workshop ❑ Workshop(s) Only ❑A ❑B
See Page 5 for pricing details.
Your customer registration code is:
When registering, please provide the code above.
Name__________________________________ Job Title ________________________
Organization____________________________________________________________
Approving Manager______________________________________________________
Address________________________________________________________________
City__________________________________State______________Zip____________
Phone________________________________Fax_______________________________
E-mail__________________________________________________________________ 5 EASY WAYS TO REGISTER:
❑ Please keep me informed via email about this and other related events.
1 Web: www.anti-infectivesummit.com
❑ Check enclosed for $_________ (Payable to IQPC)
2 Call: 1-800-882-8684
❑ Charge my __Amex __Visa __Mastercard __Diners Club
3 Email: info@iqpc.com
Card #__________________________________Exp. Date___/___ CVM code ______
4 Fax: 1-646-378-6025
Details for making payment via EFT or wire transfer can be found on
preceding page. 5 Mail: IQPC
535 5th Avenue, 8th Floor,
❑ I cannot attend, but please keep me informed of all future events. 18354.001/D/AL New York, NY 10017
Register by December 4th
and Save up to $698
Leading Companies
Anti-Infectives
TM to Present:
GlaxoSmithKline
Pfizer, Inc.
AstraZeneca
Summit
January 25-27, 2010 • Philadelphia, PA
Centers for Disease Control
and Prevention
Trius Therapeutics
Groundbreaking Advances and Key Basilea Pharmaceutical
Opinions within Anti-Infective Drug International Ltd
Discovery and Development Affinium Pharmaceutiocals
Anacor Pharmaceuticals
Media Novartis Institute for
Partners: Biomedical research
Astellas Pharma US
Enanta Pharmaceuticals
www.anti-infectivesummit.com MethylGene, Inc.